References
- Amicizia D, Arata L, Zangrillo F, Panatto D, Gasparini R. Overview of the impact of typhoid and paratyphoid fever. Utility of Ty21a vaccine (Vivotif(R). J Prev Med Hyg. 2017;58:E1–E8.
- Anonymous. WHO expert committee on biological standardization. World Health Organ Tech Rep Ser 1994;840:1–218.
- Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ. 2004;82:346–53.
- Crump JA, Mintz ED. Global trends in typhoid and paratyphoid fever. Clin Infect Dis. 2010;50:241–46. doi:https://doi.org/10.1086/648977.
- Kirk MD, Pires SM, Black RE, Caipo M, Crump JA, Devleesschauwer B, Dopfer D, Fazil A, Fischer-Walker CL, Hald T, et al. World Health Organization estimates of the global and regional disease burden of 22 foodborne bacterial, protozoal, and viral diseases, 2010: a data synthesis. PLoS Med. 2015;12:e1001921. doi:https://doi.org/10.1371/journal.pmed.1001809.
- Lopez-Gigosos R, Segura-Moreno M, Diez-Diaz R, Plaza E, Mariscal A. Commercializing diarrhea vaccines for travelers. Hum Vaccin Immunother. 2014;10:1557–67. doi:https://doi.org/10.4161/hv.27737.
- Buckle GC, Walker CL, Black RE. Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010. J Glob Health. 2012;2:010401. doi:https://doi.org/10.7189/jogh.01.010401.
- Keitel WA, Bond NL, Zahradnik JM, Cramton TA, Robbins JB. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine. 1994;12:195–99.
- Robbins JD, Robbins JB. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis. 1984;150:436–49. doi:https://doi.org/10.1093/infdis/150.3.436.
- Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, Anemona A, Habib MA, Alberto E, Juvekar S, et al. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Lancet Infect Dis. 2014;14:119–29. doi:https://doi.org/10.1016/S1473-3099(14)70940-5.
- Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas A, Hunt S, et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun. 1999;67:5806–10.
- Szu SC. Development of Vi conjugate - a new generation of typhoid vaccine. Expert Rev Vaccines. 2013;12:1273–86. doi:https://doi.org/10.1586/14760584.2013.845529.
- Mohan VK, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, Ella KM. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis. 2015;61:393–402. doi:https://doi.org/10.1093/cid/civ295.
- Micoli F, Rondini S, Pisoni I, Proietti D, Berti F, Costantino P, Rappuoli R, Szu S, Saul A, Martin LB. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine. 2011;29:712–20. doi:https://doi.org/10.1016/j.vaccine.2010.11.022.
- Jaurigue JA, Seeberger PH. Parasite carbohydrate vaccines. Front Cell Infect Microbiol. 2017;7:248.
- Jones C. Vaccines based on the cell surface carbohydrates of pathogenic bacteria. An Acad Bras Cienc. 2005;77:293–324. doi:https://doi.org/10.1590/S0001-37652005000200009.
- Link-Gelles R, Taylor T, Moore MR. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020. Vaccine. 2013;31:2572–77. doi:https://doi.org/10.1016/j.vaccine.2013.03.049.
- Thanawastien A, Cartee RT, Griffin TJ, Killeen KP, Mekalanos JJ. Conjugate-like immunogens produced as protein capsular matrix vaccines. Proc Natl Acad Sci U S A. 2015;112:E1143–51. doi:https://doi.org/10.1073/pnas.1425005112.
- Giannini G, Rappuoli R, Ratti G. The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res. 1984;12:4063–69. doi:https://doi.org/10.1093/nar/12.10.4063.
- Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother. 2013;9:2505–23. doi:https://doi.org/10.4161/hv.26109.
- Szu SC, Li XR, Stone AL, Robbins JB. Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect Immun. 1991;59:4555–61.
- Martin DG, Jarvis FG, Milner KC. Physicochemical and biological properties of sonically treated Vi antigen. J Bacteriol. 1967;94:1411–16.
- Rondini S, Micoli F, Lanzilao L, Pisoni I, Di Cioccio V, Saul AJ, Martin LB. Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM(197) glycoconjugate vaccine against Salmonella Typhi. J Infect Dev Ctries. 2012;6:763–73. doi:https://doi.org/10.3855/jidc.2495.
- Jang H, Yoon YK, Kim JA, Kim HS, An SJ, Seo JH, Cui C, Carbis R. Optimization of Vi capsular polysaccharide production during growth of Salmonella enterica serotype Typhi Ty2 in a bioreactor. J Biotechnol. 2008;135:71–77. doi:https://doi.org/10.1016/j.jbiotec.2008.02.018.
- Green MR, Pastewka JV, Peacock AC. Differential staining of phosphoproteins on polyacrylamide gels with a cationic carbocyanine dye. Anal Biochem. 1973;56:43–51. doi:https://doi.org/10.1016/0003-2697(73)90167-X.
- Hestrin S. The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application. J Biol Chem. 1949;180:249–61.
- Axelsen NH, Brock E. Electroimmunoassay (Rocket Immunoelectrophoresis). Scan J Immunol. 1983;17:103–06. doi:https://doi.org/10.1111/j.1365-3083.1983.tb04005.x.